<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37189365</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">617</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13040617</ELocationID><Abstract><AbstractText>Despite recent advances in treatment and significant improvements in prognosis, thrombosis remains the major cause of death in systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL) are the main triggers of thrombosis in patients with SLE, with a frequency of approximately 30-40%. Lupus anticoagulant, anticardiolipin, and anti-&#x3b2;2-glycoprotein I antibodies, which are included in the criteria for antiphospholipid syndrome, and 'non-criteria' aPL such as anti-phosphatidylserine/prothrombin complex antibodies, are risk factors for thrombosis in patients with SLE. Multiple positivity for aPL is also associated with an increased risk of thrombosis, and scores calculated from aPL profiles can predict the risk of developing thrombosis. Although there is insufficient evidence for treatment, aPL-positive SLE patients should/may be treated with anticoagulants and/or low-dose aspirin as appropriate. This review summarises the evidence on the clinical significance of the aPL profile as a biomarker of thrombophilia in patients with SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hisada</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4225-1639</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15W7, Kita-Ku, Sapporo 060-8638, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsumi</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15W7, Kita-Ku, Sapporo 060-8638, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="Y">Thrombophilia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiphospholipid antibody</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">thrombophilia</Keyword></KeywordList><CoiStatement>Atsumi T received speaking fees from Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Eisai Co. Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb Co., UCB Japan Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD. and Fees for consultancies from AstraZeneca plc., MEDICAL &amp; BIOLOGICAL LABORATORIES CO., LTD., Pfizer Inc., AbbVie Inc., Janssen Pharmaceutical K.K., ONO PHARMACEUTICAL CO. LTD., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., the authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37189365</ArticleId><ArticleId IdType="pmc">PMC10135455</ArticleId><ArticleId IdType="doi">10.3390/biom13040617</ArticleId><ArticleId IdType="pii">biom13040617</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>&#xdc;nl&#xfc; O., Zuily S., Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur. J. Rheumatol. 2016;3:75&#x2013;84. doi: 10.5152/eurjrheum.2015.0085.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2015.0085</ArticleId><ArticleId IdType="pmc">PMC5042235</ArticleId><ArticleId IdType="pubmed">27708976</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C., Tang S.S., To C.H., Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheumol. 2005;52:2774&#x2013;2782. doi: 10.1002/art.21224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21224</ArticleId><ArticleId IdType="pubmed">16142761</ArticleId></ArticleIdList></Reference><Reference><Citation>Avi&#xf1;a-Zubieta J.A., Vostretsova K., De Vera M.A., Sayre E.C., Choi H.K. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study. Semin. Arthritis Rheum. 2015;45:195&#x2013;201. doi: 10.1016/j.semarthrit.2015.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.05.008</ArticleId><ArticleId IdType="pmc">PMC5479699</ArticleId><ArticleId IdType="pubmed">26364556</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D., Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N. Engl. J. Med. 2018;378:2010&#x2013;2021. doi: 10.1056/NEJMra1705454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Amengual O., Atsumi T. Antiphospholipid syndrome, &#x201c;the best prophet of the future&#x201d;. Mod. Rheumatol. 2018;28:409&#x2013;416. doi: 10.1080/14397595.2018.1435988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1435988</ArticleId><ArticleId IdType="pubmed">29385876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 2009;68:238&#x2013;241. doi: 10.1136/ard.2008.093013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.093013</ArticleId><ArticleId IdType="pmc">PMC2875136</ArticleId><ArticleId IdType="pubmed">18782792</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., PG D.E.G., Koike T., Meroni P.L., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Pedrera C., Buend&#xed;a P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., Montiel-Duarte C., Torres A., Khamashta M., Velasco F. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006;54:301&#x2013;311. doi: 10.1002/art.21549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21549</ArticleId><ArticleId IdType="pubmed">16385547</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsumi T., Khamashta M.A., Haworth R.S., Brooks G., Amengual O., Ichikawa K., Koike T., Hughes G.R. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis Rheum. 1998;41:800&#x2013;807. doi: 10.1002/1529-0131(199805)41:5&lt;800::AID-ART5&gt;3.0.CO;2-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199805)41:5&lt;800::AID-ART5&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">9588730</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega-Ostertag M., Harris E.N., Pierangeli S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum. 2004;50:2911&#x2013;2919. doi: 10.1002/art.20434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20434</ArticleId><ArticleId IdType="pubmed">15457460</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi S., Braunstein E.M., Brodsky R.A. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J. Thromb. Haemost. 2021;19:607&#x2013;616. doi: 10.1111/jth.15082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15082</ArticleId><ArticleId IdType="pmc">PMC8080439</ArticleId><ArticleId IdType="pubmed">32881236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl D., Membre A., Perret-Guillaume C., Regnault V., Lecompte T. Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system. Curr. Rheumatol. Rep. 2009;11:77&#x2013;81. doi: 10.1007/s11926-009-0011-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-009-0011-7</ArticleId><ArticleId IdType="pubmed">19171115</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S., Harpel P.C., Gharavi A., Rand J., Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 1994;83:2532&#x2013;2540. doi: 10.1182/blood.V83.9.2532.2532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V83.9.2532.2532</ArticleId><ArticleId IdType="pubmed">8167338</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan G., Kriegova E., Slavik L., Mikulkova Z., Ulehlova J., Martirosyan A., Papajik T. Antiphospholipid antibody-mediated NK cell cytotoxicity. J. Reprod. Immunol. 2023;155:103791. doi: 10.1016/j.jri.2022.103791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2022.103791</ArticleId><ArticleId IdType="pubmed">36621092</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin. Immunopathol. 2022;44:347&#x2013;362. doi: 10.1007/s00281-022-00916-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00916-w</ArticleId><ArticleId IdType="pmc">PMC8816310</ArticleId><ArticleId IdType="pubmed">35122116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordin G., Boldorini R., Meroni P.L. The two hit hypothesis in the antiphospholipid syndrome: Acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus. 2003;12:851&#x2013;853. doi: 10.1191/0961203303lu445cr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu445cr</ArticleId><ArticleId IdType="pubmed">14667102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. Med. J. (Clin. Res. Ed.) 1983;287:1088&#x2013;1089. doi: 10.1136/bmj.287.6399.1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.287.6399.1088</ArticleId><ArticleId IdType="pmc">PMC1549319</ArticleId><ArticleId IdType="pubmed">6414579</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel G.J., Andreoli L., Scanzi F., Cervera R., Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J. Autoimmun. 2017;76:10&#x2013;20. doi: 10.1016/j.jaut.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.10.004</ArticleId><ArticleId IdType="pubmed">27776934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G., Egurbide M.V., Ugalde J., Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch. Intern. Med. 2004;164:77&#x2013;82. doi: 10.1001/archinte.164.1.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.1.77</ArticleId><ArticleId IdType="pubmed">14718326</ArticleId></ArticleIdList></Reference><Reference><Citation>Frodlund M., Walhelm T., Dahle C., Sj&#xf6;wall C. Longitudinal Analysis of Anti-cardiolipin and Anti-&#x3b2;2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. Front. Med. (Lausanne) 2021;8:646846. doi: 10.3389/fmed.2021.646846.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.646846</ArticleId><ArticleId IdType="pmc">PMC7959716</ArticleId><ArticleId IdType="pubmed">33732724</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignatelli P., Ettorre E., Menichelli D., Pani A., Violi F., Pastori D. Seronegative antiphospholipid syndrome: Refining the value of &#x201c;non-criteria&#x201d; antibodies for diagnosis and clinical management. Haematologica. 2020;105:562&#x2013;572. doi: 10.3324/haematol.2019.221945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2019.221945</ArticleId><ArticleId IdType="pmc">PMC7049333</ArticleId><ArticleId IdType="pubmed">32001534</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M., De Groot P.G. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2009;7:1737&#x2013;1740. doi: 10.1111/j.1538-7836.2009.03555.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03555.x</ArticleId><ArticleId IdType="pubmed">19624461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi S., McCrae K.R. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31:406&#x2013;417. doi: 10.1016/j.blre.2017.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2017.07.006</ArticleId><ArticleId IdType="pmc">PMC5714279</ArticleId><ArticleId IdType="pubmed">28784423</ArticleId></ArticleIdList></Reference><Reference><Citation>Demir S., Li J., Magder L.S., Petri M. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:3770&#x2013;3777. doi: 10.1093/rheumatology/keaa857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa857</ArticleId><ArticleId IdType="pmc">PMC8328497</ArticleId><ArticleId IdType="pubmed">33331921</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbagir S., Grosso G., Mohammed N.A., Elshafie A.I., Elagib E.M., Zickert A., Manivel V.A., Pertsinidou E., Nur M.A.M., Gunnarsson I., et al. Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. Lupus. 2021;30:1289&#x2013;1299. doi: 10.1177/09612033211014570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014570</ArticleId><ArticleId IdType="pmc">PMC8209767</ArticleId><ArticleId IdType="pubmed">33957795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl D.G., Guillemin F., de Maistre E., Perret C., Lecompte T., Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Lupus. 1997;6:467&#x2013;473. doi: 10.1177/096120339700600510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339700600510</ArticleId><ArticleId IdType="pubmed">9229367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Radin M., Cecchi I., Rubini E., Scotta A., Rolla R., Montaruli B., Pergolini P., Mengozzi G., Muccini E., et al. Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. Front. Immunol. 2019;10:376. doi: 10.3389/fimmu.2019.00376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00376</ArticleId><ArticleId IdType="pmc">PMC6411647</ArticleId><ArticleId IdType="pubmed">30891041</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese K.M.J., de Groot P.G., de Laat B., Erkan D., Favaloro E.J., Mackie I., Martinuzzo M., Ortel T.L., Pengo V., Rand J.H., et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J. Thromb. Haemost. 2020;18:2828&#x2013;2839. doi: 10.1111/jth.15047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15047</ArticleId><ArticleId IdType="pubmed">33462974</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003;101:1827&#x2013;1832. doi: 10.1182/blood-2002-02-0441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0441</ArticleId><ArticleId IdType="pubmed">12393574</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneghel L., Ruffatti A., Gavasso S., Tonello M., Mattia E., Spiezia L., Campello E., Hoxha A., Fedrigo M., Punzi L., et al. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-&#x3b2;2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin. Chem. Lab Med. 2015;53:1083&#x2013;1089. doi: 10.1515/cclm-2014-0925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2014-0925</ArticleId><ArticleId IdType="pubmed">25720075</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336:177&#x2013;178. doi: 10.1016/0140-6736(90)91697-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)91697-9</ArticleId><ArticleId IdType="pubmed">1973491</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H) Proc. Natl. Acad. Sci. USA. 1990;87:4120&#x2013;4124. doi: 10.1073/pnas.87.11.4120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.11.4120</ArticleId><ArticleId IdType="pmc">PMC54059</ArticleId><ArticleId IdType="pubmed">2349221</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., Barbui T., Zwaal R.F., Bevers E.M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544&#x2013;1547. doi: 10.1016/0140-6736(90)91374-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)91374-J</ArticleId><ArticleId IdType="pubmed">1972485</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusch A. The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. Antibodies (Basel) 2016;5:16. doi: 10.3390/antib5020016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib5020016</ArticleId><ArticleId IdType="pmc">PMC6698844</ArticleId><ArticleId IdType="pubmed">31557997</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Gu J., Wan L., Hu Q., Teng J., Liu H., Cheng X., Ye J., Su Y., Sun Y., et al. &#x201c;Non-criteria&#x201d; antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res. Ther. 2020;22:33. doi: 10.1186/s13075-020-2131-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-2131-4</ArticleId><ArticleId IdType="pmc">PMC7035660</ArticleId><ArticleId IdType="pubmed">32085759</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717&#x2013;2723. doi: 10.1182/blood-2002-11-3334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-11-3334</ArticleId><ArticleId IdType="pubmed">12816875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrani T., Petri M. IgM anti-&#x3b2;2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J. Rheumatol. 2011;38:450&#x2013;453. doi: 10.3899/jrheum.100650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100650</ArticleId><ArticleId IdType="pubmed">21123325</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsumi T., Ieko M., Bertolaccini M.L., Ichikawa K., Tsutsumi A., Matsuura E., Koike T. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982&#x2013;1993. doi: 10.1002/1529-0131(200009)43:9&lt;1982::AID-ANR9&gt;3.0.CO;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200009)43:9&lt;1982::AID-ANR9&gt;3.0.CO;2-2</ArticleId><ArticleId IdType="pubmed">11014348</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandevelde A., Chayoua W., de Laat B., Moore G.W., Musia&#x142; J., Zuily S., Wahl D., Devreese K.M.J. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J. Thromb. Haemost. 2022;20:2136&#x2013;2150. doi: 10.1111/jth.15785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15785</ArticleId><ArticleId IdType="pubmed">35713971</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R., Cheng C.Y., Yang Y., Denas G., Pengo V. Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis. Thromb. Res. 2022;214:106&#x2013;114. doi: 10.1016/j.thromres.2022.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.04.021</ArticleId><ArticleId IdType="pubmed">35526513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham M., Orsolini G., Crowson C., Snyder M., Pruthi R., Moder K. Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population. J. Thromb. Haemost. 2022;20:2070&#x2013;2074. doi: 10.1111/jth.15792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15792</ArticleId><ArticleId IdType="pubmed">35722911</ArticleId></ArticleIdList></Reference><Reference><Citation>de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540&#x2013;1545. doi: 10.1182/blood-2004-09-3387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-09-3387</ArticleId><ArticleId IdType="pubmed">15507529</ArticleId></ArticleIdList></Reference><Reference><Citation>de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., Ruffatti A., Rozman B., Kveder T., de Moerloose P., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study. J. Thromb. Haemost. 2009;7:1767&#x2013;1773. doi: 10.1111/j.1538-7836.2009.03588.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03588.x</ArticleId><ArticleId IdType="pubmed">19694946</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M., Cecchi I., Roccatello D., Meroni P.L., Sciascia S. Prevalence and Thrombotic Risk Assessment of Anti-&#x3b2;2 Glycoprotein I Domain I Antibodies: A Systematic Review. Semin. Thromb. Hemost. 2018;44:466&#x2013;474. doi: 10.1055/s-0037-1603936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1603936</ArticleId><ArticleId IdType="pubmed">28778105</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericleous C., D&#x2019;Souza A., McDonnell T., Ripoll V.M., Leach O., Isenberg D., Giles I., Rahman A. Antiphospholipid antibody levels in early systemic lupus erythematosus: Are they associated with subsequent mortality and vascular events? Rheumatology (Oxford) 2020;59:146&#x2013;152. doi: 10.1093/rheumatology/kez239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez239</ArticleId><ArticleId IdType="pmc">PMC6909892</ArticleId><ArticleId IdType="pubmed">31257438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura H., Oku K., Amengual O., Ohmura K., Fujieda Y., Kato M., Bohgaki T., Yasuda S., Atsumi T. First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-&#x3b2;(2) -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies Tests. Arthritis Care Res. (Hoboken) 2018;70:627&#x2013;634. doi: 10.1002/acr.23310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23310</ArticleId><ArticleId IdType="pubmed">28686816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Garc&#xed;a R., Serrano M., Mart&#xed;nez-Flores J., Mora S., Morillas L., Mart&#xed;n-Mola M., Morales J.M., Paz-Artal E., Serrano A. Isolated IgA anti- &#x3b2;2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J. Immunol. Res. 2014;2014:704395. doi: 10.1155/2014/704395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/704395</ArticleId><ArticleId IdType="pmc">PMC3987939</ArticleId><ArticleId IdType="pubmed">24741618</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlagea A., Pascual-Salcedo D., &#xc1;lvarez Doforno R., Lavilla P., Diez J., Padilla Merlano B., Cuesta M.V., Gil A. IgA anti-&#x3b2;2 glycoprotein I antibodies: Experience from a large center. Thromb. Res. 2018;162:38&#x2013;43. doi: 10.1016/j.thromres.2017.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2017.12.007</ArticleId><ArticleId IdType="pubmed">29274563</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy V., Willis R., Romay-Penabad Z., Ruiz-Lim&#xf3;n P., Mart&#xed;nez-Mart&#xed;nez L.A., Jatwani S., Jajoria P., Seif A., Alarc&#xf3;n G.S., Papalardo E., et al. Value of isolated IgA anti-&#x3b2;2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013;65:3186&#x2013;3193. doi: 10.1002/art.38131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38131</ArticleId><ArticleId IdType="pmc">PMC4048705</ArticleId><ArticleId IdType="pubmed">23983008</ArticleId></ArticleIdList></Reference><Reference><Citation>Danowski A., Kickler T.S., Petri M. Anti-beta2-glycoprotein I: Prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheumatol. 2006;33:1775&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960938</ArticleId></ArticleIdList></Reference><Reference><Citation>Chayoua W., Yin D.M., Kelchtermans H., Moore G.W., Gris J.C., Musia&#x142; J., Zuily S., Ten Cate H., de Laat B., Devreese K.M.J. Is There an Additional Value in Detecting Anticardiolipin and Anti-&#x3b2;2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome? Thromb. Haemost. 2020;120:1557&#x2013;1568. doi: 10.1055/s-0040-1714653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1714653</ArticleId><ArticleId IdType="pubmed">32696448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradacova P., Slavik L., Ulehlova J., Skoumalova A., Ullrychova J., Prochazkova J., Hlusi A., Manukyan G., Kriegova E. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines. 2021;9:166. doi: 10.3390/biomedicines9020166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9020166</ArticleId><ArticleId IdType="pmc">PMC7914732</ArticleId><ArticleId IdType="pubmed">33567576</ArticleId></ArticleIdList></Reference><Reference><Citation>de Laat B., Derksen R.H., Mackie I.J., Roest M., Schoormans S., Woodhams B.J., de Groot P.G., van Heerde W.L. Annexin A5 polymorphism (&#x2212;1C&#x2192;T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann. Rheum. Dis. 2006;65:1468&#x2013;1472. doi: 10.1136/ard.2005.045237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.045237</ArticleId><ArticleId IdType="pmc">PMC1798354</ArticleId><ArticleId IdType="pubmed">16449315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaburaki J., Kuwana M., Yamamoto M., Kawai S., Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am. J. Hematol. 1997;54:209&#x2013;213. doi: 10.1002/(SICI)1096-8652(199703)54:3&lt;209::AID-AJH6&gt;3.0.CO;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-8652(199703)54:3&lt;209::AID-AJH6&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">9067499</ArticleId></ArticleIdList></Reference><Reference><Citation>Arachchillage D.R., Efthymiou M., Mackie I.J., Lawrie A.S., Machin S.J., Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J. Thromb. Haemost. 2014;12:1801&#x2013;1809. doi: 10.1111/jth.12722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12722</ArticleId><ArticleId IdType="pubmed">25196808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Mackie I., Nallamilli S., Pires T., Moll R., Pericleous C., Isenberg D.A., Cohen H., Efthymiou M. Anti-protein C antibodies and acquired protein C resistance in SLE: Novel markers for thromboembolic events and disease activity? Rheumatology (Oxford) 2021;60:1376&#x2013;1386. doi: 10.1093/rheumatology/keaa509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa509</ArticleId><ArticleId IdType="pubmed">32964932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V., Ruffatti A., Legnani C., Gresele P., Barcellona D., Erba N., Testa S., Marongiu F., Bison E., Denas G., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010;8:237&#x2013;242. doi: 10.1111/j.1538-7836.2009.03674.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03674.x</ArticleId><ArticleId IdType="pubmed">19874470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzaro N., Ghirardello A., Zampieri S., Iaccarino L., Tozzoli R., Ruffatti A., Villalta D., Tonutti E., Doria A. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: A 15-year longitudinal study. J. Thromb. Haemost. 2007;5:1158&#x2013;1164. doi: 10.1111/j.1538-7836.2007.02532.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02532.x</ArticleId><ArticleId IdType="pubmed">17388963</ArticleId></ArticleIdList></Reference><Reference><Citation>Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., Horita T., Yasuda S., Koike T. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504&#x2013;512. doi: 10.1002/art.33340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33340</ArticleId><ArticleId IdType="pubmed">21953404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Bertolaccini M.L., Roccatello D., Khamashta M.A. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann. Rheum. Dis. 2013;72:142&#x2013;143. doi: 10.1136/annrheumdis-2012-201985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201985</ArticleId><ArticleId IdType="pubmed">22843492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Sun S., Yan Q., Bao C., Fu Q. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: A validation study. Clin. Rheumatol. 2016;35:333&#x2013;340. doi: 10.1007/s10067-015-3159-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3159-8</ArticleId><ArticleId IdType="pubmed">26753544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisada R., Kato M., Sugawara E., Fujieda Y., Oku K., Bohgaki T., Amengual O., Yasuda S., Atsumi T. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study. J. Thromb. Haemost. 2017;15:1782&#x2013;1787. doi: 10.1111/jth.13763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13763</ArticleId><ArticleId IdType="pubmed">28662299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Bertolaccini M.L. Thrombotic risk assessment in APS: The Global APS Score (GAPSS) Lupus. 2014;23:1286&#x2013;1287. doi: 10.1177/0961203314541317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314541317</ArticleId><ArticleId IdType="pubmed">25228728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Radin M., Sanna G., Cecchi I., Roccatello D., Bertolaccini M.L. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: A pooled analysis. Rheumatology (Oxford) 2018;57:661&#x2013;665. doi: 10.1093/rheumatology/kex466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex466</ArticleId><ArticleId IdType="pubmed">29342292</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M., Sciascia S., Erkan D., Pengo V., Tektonidou M.G., Ugarte A., Meroni P., Ji L., Belmont H.M., Cohen H., et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin. Arthritis Rheum. 2019;49:464&#x2013;468. doi: 10.1016/j.semarthrit.2019.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC7402528</ArticleId><ArticleId IdType="pubmed">31153708</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno M.N.D., Scalera A., Tufano A., Ambrosino P., Bettiol A., Silvestri E., Emmi G., Prisco D. The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis. 2018;278:60&#x2013;65. doi: 10.1016/j.atherosclerosis.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2018.09.010</ArticleId><ArticleId IdType="pubmed">30253290</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Homood I.A. Thrombosis in systemic lupus erythematosus: A review article. ISRN Rheumatol. 2012;2012:428269. doi: 10.5402/2012/428269.</Citation><ArticleIdList><ArticleId IdType="doi">10.5402/2012/428269</ArticleId><ArticleId IdType="pmc">PMC3413961</ArticleId><ArticleId IdType="pubmed">22900201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarr T., Lakos G., Bhattoa H.P., Shoenfeld Y., Szegedi G., Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16:39&#x2013;45. doi: 10.1177/0961203306074767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306074767</ArticleId><ArticleId IdType="pubmed">17283584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29&#x2013;36. doi: 10.1002/art.24232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24232</ArticleId><ArticleId IdType="pubmed">19116963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L., Mathian A., Devilliers H., Ruffatti A., Tektonidou M., Forastiero R., Pengo V., Lambert M., Lefevre G., Martinez-Zamora M.A., et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 2015;14:192&#x2013;200. doi: 10.1016/j.autrev.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.10.019</ArticleId><ArticleId IdType="pubmed">25461472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bala M.M., Paszek E., Lesniak W., Wloch-Kopec D., Jasinska K., Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst. Rev. 2018;7:Cd012534. doi: 10.1002/14651858.CD012534.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012534.pub2</ArticleId><ArticleId IdType="pmc">PMC6513409</ArticleId><ArticleId IdType="pubmed">30004572</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G., Andreoli L., Limper M., Amoura Z., Cervera R., Costedoat-Chalumeau N., Cuadrado M.J., D&#xf6;rner T., Ferrer-Oliveras R., Hambly K., et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 2019;78:1296&#x2013;1304. doi: 10.1136/annrheumdis-2019-215213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W.Y., Saver J.L., Wu Y.L., Lin C.J., Lee M., Ovbiagele B. Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2019;76:906&#x2013;914. doi: 10.1001/jamaneurol.2019.1120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1120</ArticleId><ArticleId IdType="pmc">PMC6515567</ArticleId><ArticleId IdType="pubmed">31081871</ArticleId></ArticleIdList></Reference><Reference><Citation>Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun. Rev. 2015;14:358&#x2013;362. doi: 10.1016/j.autrev.2014.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.12.006</ArticleId><ArticleId IdType="pubmed">25534016</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkan D., Yazici Y., Peterson M.G., Sammaritano L., Lockshin M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924&#x2013;929. doi: 10.1093/rheumatology/41.8.924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/41.8.924</ArticleId><ArticleId IdType="pubmed">12154210</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkan D., Unlu O., Sciascia S., Belmont H.M., Branch D.W., Cuadrado M.J., Gonzalez E., Knight J.S., Uthman I., Willis R., et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27:399&#x2013;406. doi: 10.1177/0961203317724219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317724219</ArticleId><ArticleId IdType="pubmed">28764618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravvariti E., Koutsogianni A., Samoli E., Sfikakis P.P., Tektonidou M.G. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun. Rev. 2020;19:102491. doi: 10.1016/j.autrev.2020.102491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102491</ArticleId><ArticleId IdType="pubmed">32084592</ArticleId></ArticleIdList></Reference><Reference><Citation>Meroni P.L., Raschi E., Testoni C., Tincani A., Balestrieri G., Molteni R., Khamashta M.A., Tremoli E., Camera M. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870&#x2013;2878. doi: 10.1002/1529-0131(200112)44:12&lt;2870::AID-ART475&gt;3.0.CO;2-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200112)44:12&lt;2870::AID-ART475&gt;3.0.CO;2-Y</ArticleId><ArticleId IdType="pubmed">11762948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A., Hutten B.A., Jaff M.R., Manja V., Schulman S., et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693&#x2013;4738. doi: 10.1182/bloodadvances.2020001830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001830</ArticleId><ArticleId IdType="pmc">PMC7556153</ArticleId><ArticleId IdType="pubmed">33007077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V., Denas G., Zoppellaro G., Jose S.P., Hoxha A., Ruffatti A., Andreoli L., Tincani A., Cenci C., Prisco D., et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365&#x2013;1371. doi: 10.1182/blood-2018-04-848333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-04-848333</ArticleId><ArticleId IdType="pubmed">30002145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordi-Ros J., S&#xe1;ez-Comet L., P&#xe9;rez-Conesa M., Vidal X., Riera-Mestre A., Castro-Salom&#xf3; A., Cuquet-Pedragosa J., Ortiz-Santamaria V., Mauri-Plana M., Sol&#xe9; C., et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann. Intern. Med. 2019;171:685&#x2013;694. doi: 10.7326/M19-0291.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-0291</ArticleId><ArticleId IdType="pubmed">31610549</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V., Hoxha A., Andreoli L., Tincani A., Silvestri E., Prisco D., Fierro T., Gresele P., Cafolla A., De Micheli V., et al. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. J. Thromb. Haemost. 2021;19:531&#x2013;535. doi: 10.1111/jth.15158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15158</ArticleId><ArticleId IdType="pubmed">33128325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuily S., Cohen H., Isenberg D., Woller S.C., Crowther M., Dufrost V., Wahl D., Dor&#xe9; C.J., Cuker A., Carrier M., et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2020;18:2126&#x2013;2137. doi: 10.1111/jth.14935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14935</ArticleId><ArticleId IdType="pubmed">32881337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile I., Granata F., Punziano A., de Paulis A., Rossi F.W. Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It? Biomedicines. 2021;9:132. doi: 10.3390/biomedicines9020132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9020132</ArticleId><ArticleId IdType="pmc">PMC7911562</ArticleId><ArticleId IdType="pubmed">33535377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>